Hope for elderly as vaccine shows 94% protection

Experts have welcomed the news that the promising Covid vaccine candidate developed by Pfizer is effective among the elderly. Data from Pfizer and BioNTech’s phase 3 trial show their vaccine is 94% effective in those aged 65 and older. Scientists have welcomed the news that older people will achieve a good level of protection, with those over 65 years deemed to be at higher risk of severe illness from Covid-19 or death. One expert said that the findings among the elderly “surpass expectations”.